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Abstract
Background: The increasing number of patients, the high costs of management, and the chronic progress of the disease that
prevents patients from performing even simple daily activities make Parkinson disease (PD) a complex pathology with a high
impact on society. In particular, patients implanted with deep brain stimulation (DBS) electrodes face a highly fragile stabilization
period, requiring specific support at home. However, DBS patients are followed usually by untrained personnel (caregivers or
family), without specific care pathways and supporting systems.
Objective: This projects aims to (1) create a reference consensus guideline and a shared requirements set for the homecare and
monitoring of DBS patients, (2) define a set of biomarkers that provides alarms to caregivers for continuous home monitoring,
and (3) implement an information system architecture allowing communication between health care professionals and caregivers
and improving the quality of care for DBS patients.
Methods: The definitions of the consensus care pathway and of caregiver needs will be obtained by analyzing the current
practices for patient follow-up through focus groups and structured interviews involving health care professionals, patients, and
caregivers. The results of this analysis will be represented in a formal graphical model of the process of DBS patient care at home.
To define the neurophysiological biomarkers to be used to raise alarms during the monitoring process, neurosignals will be
acquired from DBS electrodes through a new experimental system that records while DBS is turned ON and transmits signals by
radiofrequency. Motor, cognitive, and behavioral protocols will be used to study possible feedback/alarms to be provided by the
system. Finally, a set of mobile apps to support the caregiver at home in managing and monitoring the patient will be developed
and tested in the community of caregivers that participated in the focus groups. The set of developed apps will be connected to
the already existing WebBioBank Web-based platform allowing health care professionals to manage patient electronic health
records and neurophysiological signals. New modules in the WebBioBank platform will be implemented to allow integration and
data exchange with mobile health apps.
Results: The results of this project will provide a novel approach to long-term evaluation of patients with chronic, severe
conditions in the homecare environment, based on caregiver empowerment and tailored applications developed according to
consensus care pathways established by clinicians.
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Conclusions: The creation of a direct communication channel between health care professionals and caregivers can benefit
large communities of patients and would represent a scalable experience in integrating data and information coming from a clinical
setting to those in home monitoring.
(JMIR Res Protoc 2015;4(1):e30)   doi:10.2196/resprot.4044
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Introduction
Background
Parkinson disease (PD) is a common neurodegenerative disorder
affecting about 1% of the population over the age of 60 years
[1]. PD is typically characterized by motor symptoms; however
the clinical spectrum of the disease is more extensive, covering
a wide range of nonmotor symptoms including cognitive and
behavioral changes, sleep disorders, autonomic dysfunctions,
sensory symptoms, and fatigue [2,3]. The surgical treatment of
PD was reintroduced in the late 1990s with the advent of
subthalamic deep brain stimulation (DBS) [4,5], and this is now
an established treatment for PD patients [6-9].
Follow-up studies in PD show that after DBS surgery, motor
function and performance during daily living activities improve
for up to 5 to 10 years, although the initial benefit in part
progressively deteriorates [10] and patients still experience
clinical fluctuations that prevent them from performing simple
daily activities [11]. In addition, immediately after surgery` PD
patients face a highly fragile stabilization period, in which
parameters are set and patients and families get used to the new
situation introduced with DBS.
The long-term outcome of DBS depends on the development
of unresponsive PD disturbances related to disease progression
that should be properly monitored to allow early recognition
and treatment [9].
Long-term PD disability involves motor and nonmotor
symptoms that worsen in time. Cognitive impairment and
dementia have a higher prevalence in older patients [12,13].
Dementia and hallucinations predict nursing home placement
and seem to double the mortality risk especially in older PD
patients [14]. Another common, bothersome nonmotor symptom
is the onset of lower urinary tract symptoms [15]. Up to 68%
of PD patients fall every year, with approximately 50% falling
repeatedly [16]. Cognitive behavioral education and exercise
training were suggested to be effective in reducing the risk of
falls [17,18]. Pain affects 29% to 85% of PD patients who
experience various types of pain that may fluctuate with motor
symptoms as “nonmotor fluctuations” [19]; the pain improves
after DBS [20].
PD progression often leads to hospitalization [21]. The most
frequent causes for admission are falls, pneumonia, urinary tract
infections, reduced mobility, psychiatric disorders, and mental
status changes [22]. PD progression in DBS patients is
monitored in scheduled follow-up clinical visits (once or twice
a year) when the neurologist takes an instantaneous picture of
the patient’s condition that cannot completely reflect the daily
condition. At home, patients rely on a family caregiver, who is
usually not trained to deal with PD progression and DBS. Often,
the reference center is far from the patient's house.
Research carried out in the last 15 years shows that recordings
of neuronal activity (local field potentials [LFPs]) from the
implanted electrodes provide information related to the patient's
state [23-34]. LFPs correlate with motor and nonmotor PD
symptoms and were recently proposed as a feedback variable
for new DBS systems able to adapt stimulation parameters to
the patient’s state [11]. Provided that the new generation of
DBS stimulators will allow LFP recordings during stimulation
[11], it is likely that the analysis of neuronal activity in DBS
patients can be integrated into monitoring systems to provide
feedback and alarms.
These observations suggest that monitoring DBS patients more
closely and continuously might be crucial to ensure a better
quality of life. The use of telemedicine for monitoring PD
patients has attracted a lot of attention [35-38], but no
technology has been developed to support the continuous
monitoring of DBS patients at home, including
neurophysiological monitoring, together with an effective
empowerment tool for caregivers.
Objectives
Consensus Guideline and Requirements Set
The reference guideline will be developed by the
multiprofessional team responsible for the patient’s care
(neurologist, neurophysiologist, nurse, psychologist,
physiotherapist, speech therapist) via modeling and defining
the clinical care pathway of the DBS PD patient at home. In
addition, the team will work with associates of the patient to
establish a shared set of needs of the caregiver and patient
community for the optimal management of patients with PD
undergoing DBS at home.
Neurophysiological Biomarkers
Neurophysiological biomarkers provided by the neuronal signals
recorded from deep brain electrodes can be used to directly
monitor the patient's state at home. Motor, cognitive, and
behavioral protocols will be used to study possible
feedback/alarms to be provided by the system. These biomarkers
will ground the future management of DBS PD patients at home,
with the implanted stimulators being part of a system, already
available as an experimental device, that will be able to record
from DBS electrodes while stimulating.
Information System Architecture
The architecture of the information system will be created to
meet the specific needs of caregivers at home by integrating the
clinical care pathway of the patient in order to provide a
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caregiver support system connected to and sharing information
with the electronic health record of the patient. The platform
will be able to manage neurosignals analysis and provide alerts
related to changes in biomarkers underlying changes in the
patient's state. The architecture will hence be specific for home
telemonitoring of DBS PD patients and empowerment of
caregivers and include educational material, a direct
communication channel with the specialist, and operative
instructions for the recognition and management of simple alert
symptoms.
Methods
Defining and Modeling the Process of Homecare
Monitoring for DBS Patients
To achieve the definition of the consensus care pathway for PD
patients with DBS implant and establish a shared set of caregiver
needs, we will analyze the current management practices by
involving neurologists and psychologists (maximum 15) from
the DBS Study Group of the Italian Neurological Society
(Società Italiana di Neurologia) and organizing a focus group
dedicated to homecare management of patients. The focus group
will draft a consensus clinical care pathway that will be validated
by a larger group of at least 30 PD experts.
We will then prepare structured interviews for patients and
caregivers to establish their main needs while at home, and we
will interview patients and caregivers recruited through the
Associazione Italiana Parkinson and directly through the
Movement Disorders Ambulatory of both the Borgoroma
Hospital and the Fondazione IRCCS Ca’Granda Ospedale
Maggiore Policlinico. The expected number of patients and
caregivers to be interviewed is 50.
Finally, we will involve 10 to 15 patients, together with their
caregivers and reference neurologists, in a focus group dedicated
to the definition of the main needs and requirements for home
monitoring support systems starting from the results of the
interviews.
After having completed the needs analysis for both health care
professionals and patients and families, we will model through
a graphical language (Unified Modeling Language [UML]) the
care pathway of the PD patients with DBS at home, according
to the clinical care pathway and the patient and caregiver needs.
UML is a widely used visual language for specifying,
visualizing, constructing, and documenting the artifacts of
software systems, as well as for business modeling and other
nonsoftware applications [39,40]. A UML model is composed
of diagrams modeling the static and dynamic behaviors of the
system/process. The UML modeling approach is based on the
decomposition of a complex system into many different objects
representing the subjects/objects related through hierarchical
and functional relationships and specified through properties.
The methods available to each object represent all the actions
that the object exposes or receives. The methods available map
all the existing interactions between objects in the system. This
decomposed and simplified structure allows the introduction of
a formal representation and supports the verification of its
validity.
Defining Neurophysiological Biomarkers
To define neurophysiological biomarkers (Table 1) providing
feedback on the patient’s state, we will record LFPs from 30
patients affected by PD and implanted with subthalamic nucleus
DBS electrodes through a new experimental system that records
LFPs while DBS is ON [41] and transmits signals by
radiofrequency to a recording system (Figure 1). Recordings
will take place 2 to 3 days after the surgery for electrode
implantation and will record continuously for 3 hours. All of
the experimental sessions will be videorecorded to allow further
offline reassessment of the patient’s state by an experienced
neurologist in order to detect motor fluctuations and other
symptoms that may require feedback to the caregiver or to the
reference neurologist.
LFPs will be bipolarly recorded through DBS electrodes
(Medtronic 3389) implanted in the subthalamic nucleus. The
DBS electrode has four cylindrical contacts (0, 1, 2, and 3
beginning from the most caudal). Two contacts will be used for
recording and one for DBS delivery. LFPs will be recorded
through a new system (aDBS, Newronika srl) that allows LFP
recording with DBS ON [41]; control of DBS parameters,
manual and automatic, through ad hoc algorithms; and
radiofrequency transmission of recorded signals.
LFP analysis will be conducted offline with ad hoc programs
stored on the WebBioBank system for clinical data collection.
These Matlab-based programs allow signal preprocessing and
analysis and were previously used for other LFP analyses
[25,26,28,33].
Because LFPs represent the activity of large populations of
neurons, the analysis will be carried out in the frequency
domain. Spectral analysis (power spectrum), cross-spectral
analysis (coherence), parametric and nonparametric
time-frequency analysis, and bispectral analysis (bicoherence)
will be applied to extract biomarkers. Parametric and
nonparametric tests will be used to evaluate the intrasubjective
changes of LFP biomarkers in different conditions and during
different tasks.
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Table 1. Protocols for defining neurophysiological biomarkers.
DBSLFP recording
After 12 hours withdrawal of antiparkinsonian therapy:
OffRest (with the patient lying in an armchair or on a bed)
OnRest (with the patient lying in an armchair or on a bed)
OffMovement (during self-paced repetitive movement of one arm/leg, during cued movements of the limbs, and during
spontaneous walking around the room)
OnMovement (during self-paced repetitive movement of one arm/leg, during cued movements of the limbs, and during
spontaneous walking around the room)
OffEmotional and decision-making tasks (during an emotional task—patient will be shown pictures/movies that elicit emo-
tional response—and during a decision-making task—patient must choose an answer to moral and neutral questions)
OnEmotional and decision-making tasks (during an emotional task—patient will be shown pictures/movies that elicit emo-
tional response—and during a decision-making task—patient must choose an answer to moral and neutral questions)
After the administration of a clinically effective dose of levodopa:
OffRest (with the patient lying in an armchair or on a bed)
OnRest (with the patient lying in an armchair or on a bed)
OffMovement (during self-paced repetitive movement of one arm/leg, during cued movements of the limbs, and during
spontaneous walking around the room)
OnMovement (during self-paced repetitive movement of one arm/leg, during cued movements of the limbs, and during
spontaneous walking around the room)
OffEmotional and decision-making tasks (during an emotional task—patient will be shown pictures/movies that elicit emo-
tional response—and during a decision-making task—patient must choose an answer to moral and neutral questions)
OnEmotional and decision-making tasks (during an emotional task—patient will be shown pictures/movies that elicit emo-
tional response—and during a decision-making task—patient must choose an answer to moral and neutral questions)
Figure 1. LFPs are recorded bipolarly from the DBS electrodes while the stimulation is turned ON through the aDBS device that also allows DBS
parameter change and radiofrequency transmission of the recorded signals.
Defining the Architecture of the Integrated Telecare
System
The implementation of the system architecture will be based
on the extension of the already-existing WebBioBank system
for the management of electronic health records (EHR) of PD
patients with DBS electrode implants, integrated with signal
analysis [42]. The system will be extended with a set of mobile
apps to support the caregiver in managing and monitoring the
patient at home.
The architecture will consist of two modules, Care Pathway and
Caregiver Support, which are both connected to the
WebBioBank Web-based platform (Figure 2). The Care Pathway
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module will be a part of the WebBioBank EHR system and will
be devoted to supporting the continuous monitoring of the
disease progression and updating of home treatments,
customized for each patient. The Caregiver Support module
will be designed to provide the tools and information the patient
and caregiver need for the proper implementation of the Care
Pathway, according to the needs and requirements defined in
the first phase of the project. A set of mobile apps will be made
available to patients and caregivers to support symptom
interpretation, emergency management, and routine daily
activities and allow information exchange with the reference
neurologist. A mobile device, such as a tablet, will be provided
to patients who do not have a personal one.
The system will be implemented and preliminary tested (alpha
test) on the same patients involved in the focus groups
previously described. System validation will be not part of this
project.
Figure 2. Expected architecture of the prototype system. The WebBioBank Web-based platform supports the information exchange between the Care
Pathway module that defines the configuration of the homecare monitoring/treatments and the Caregiver Support module, a mobile app dedicated to
the caregiver.
Results
The project is supported by preliminary observations showing
that PD patient and caregiver associations are already active in
asking for more effective communication with their care team
and reliable education sources for the management of patients
in homecare. Also, our previous studies show that
neurophysiological signals from DBS electrodes provide
information on PD motor and nonmotor symptoms [11,34], and
we have already implemented a platform for the management
and analysis of biopotentials recorded from DBS electrodes,
integrated with WebBioBank [42].
We expect at the end of the project to obtain a reference
consensus guideline and a shared requirements set for the home
monitoring and care of patients with PD treated with DBS that,
combined with the set of biomarkers that will provide
alarms/feedback to caregivers and health care professionals
regarding the patient’s state, will constitute the implementation
of continuous home monitoring for DBS patients. The
implementation of a prototype information system architecture
allowing communication between health care professionals and
caregivers will support the improvement of the quality of care
for PD patients treated with DBS.
Discussion
Patients with PD undergoing DBS face a highly fragile
stabilization period and require specific support at home. At
present, no system for DBS home monitoring is available. Our
project, introducing effective direct and continuous monitoring
of patients at home, would help not only to assess PD
progression but also to make the patients and their families
central actors in the care process.
More specifically, the definition of consensus care pathways
for patient home monitoring, the definition of
neurophysiological biomarkers from signals recorded through
DBS electrode, and the in-depth analysis of caregiver needs
will ground the development of supporting tools and
telemonitoring of DBS PD patients at home. Properly integrated
with patient EHRs, these tools will improve the quality of life
for DBS PD patients by supporting caregivers, optimizing
patient continuous monitoring, and providing alerts to
professionals and caregivers about disease worsening or
reprogramming needs.
The project results will contribute to the integration of the
caregiver role in the care pathway of the patient through a direct
communication channel between health care professionals and
caregivers by means of an enhanced and easily accessible mobile
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app system for DBS patient home monitoring. In the project,
we will also address the issue of ongoing support to caregivers
through dedicated apps facilitating their education and
interaction with local resources. Also, the definitions by
clinicians of consensus care pathways and personalized care
plans may produce better resource management for the national
health care service and may improve, in terms of effectiveness
and efficiency, the management of this costly neurodegenerative
chronic disease.
The experience in integrating data and information coming from
a clinical setting to those in home monitoring can be scalable
to other conditions involving patients with chronic diseases in
the homecare environment, and tailored apps can be developed
according to consensus care pathways established by clinicians.
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